Frontier Bio develops engineered blood vessels as foundation for lab-grown organs
Summary
Frontier Bio is developing tissue-engineered blood vessels (vascular grafts) and in-vitro tissue platforms, aiming to address the global organ shortage crisis. With only 10% of global organ demand being met and over 150,000 organ transplants performed annually, the company focuses on creating living vascular grafts as the foundational building blocks for engineering entire organs. Their approach targets eliminating the need for organ donors and animal testing by enabling on-demand human tissue production.
Source
Twitter / XFrontier Bio develops engineered blood vessels as foundation for lab-grown organsfrontierbio.comKey quotes
· 3 pulledFrontier Bio is paving the way for a future where organ donors are no longer needed, and animal testing is a thing of the past.
Engineering a new organ is impossible without its vascular system... blood vessels are the key.
Only 10% of Global Organ Demand is Met
You might also wanna read
BIO Launches National Campaign Highlighting Patient Stories Behind Biotechnology Breakthroughs
The Biotechnology Innovation Organization (BIO) has launched a national campaign called "The Fight of Our Lives" to highlight the human stor
bio.org·14d ago
Study Shows Low-Cost Portable Biotech Tools Can Expand Access to Research and Diagnostics in Resource-Limited Settings
A global research team led by University of Toronto's Leslie Dan Faculty of Pharmacy has demonstrated the effectiveness of low-cost, portabl
genengnews.com·15d ago
Parallel Bio relocates to Bay Area with $30M to replace animal drug testing with organoids
Parallel Bio, a biotech startup co-founded by Robert DiFazio and Juliana Hilliard, has relocated from Boston to the Bay Area after raising $
bizjournals.com·8d ago
Biohub Seeks Optical Engineer for Advanced Light Sheet Microscopy in AI-Driven Biomedical Research
Biohub is a 501(c)(3) biomedical research organization building the first large-scale scientific initiative that combines frontier AI models
Protuoso Biosciences raises $9.5M for AI-designed multifunctional biologic drugs
Protuoso Biosciences, a California-based startup, has raised $9.5 million to advance its AI-designed multifunctional biologics platform. The
longevity.technology·25d ago
China creates new regulatory pathway to accelerate access to advanced biomedical therapies
China has established a new regulatory "tech track" for advanced therapies like personalized cancer treatments, cell and gene therapies, and
biopharmadive.com·9d agoComments
Sign in to join the conversation.
No comments yet. Be the first.